Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study

Figures & data

Table 1. Characteristics of the study population.

Variables	Mean (SD)
Age (years)	73.2 (6.7)
BMI	23.5 (2.8)
BMD/YAM ratio (%)	103.3 (19.7)
Muscle volume	3.8 (2.2)
Hb (mg/dL)	14.1 (2.3)
TG (mg/mL)	135 (64)
LDL (mg/mL)	105 (26)
HDL (mg/mL)	53 (15)
BS (mg/dL)	123 (33)
Prostatic volume (mL)	44.2 (20.3)
PVR (mL)	73 (73)
IPSS	15.7 (7.5)
OABSS	5.3 (3.0)
IIEF5	7.0 (7.1)
TT (mg/mL)	4.60 (1.52)
FT (pg/mL)	6.10 (2.32)

BMI, body mass index; BMD, bone mineral density; Hb, hemoglobin; TG, triglyceride; BS, blood sugar; PVR, post-voided residual volume; IPSS, International Index of Prostatic Symptom score; OABSS, Overactive Bladder Symptom score; TT, total testosterone; FT, free testosterone.

Table 2. Comparisons of study variables between the groups.

	Rate of TT increase, mean (SD)
Variables	Group A(n = 42)	Group B (n = 34)	p
Age (years)	72.5 (7.0)	74.1 (6.7)	0.397
BMI	23.3 (2.5)	23.4 (3.2)	0.277
BMD/YAM ratio (%)	105.4 (22.1)	101.5 (16.9)	0.197
Muscle volume	3.7 (2.4)	3.8 (2.0)	0.456
Hb (mg/dL)	11.4 (1.2)	14.0 (3.3)	0.201
TG (mg/mL)	146 (66)	131 (71)	0.179
LDL (mg/mL)	105 (26)	104 (26)	0.390
HDL (mg/mL)	54 (15)	52 (14)	0.292
BS (mg/dL)	120 (28)	126 (39)	0.224
Prostatic volume (mL)	46.6 (19.0)	45.9 (21.8)	0.242
PVR (mL)	74 (78)	66 (68)	0.369
IPSS	16.6 (7.6)	15.0 (7.5)	0.187
OABSS	5.3 (3.9)	5.1 (3.1)	0.403
IIEF5	5.9 (6.6)	8.1 (7.6)	0.0921
TT (mg/mL)	4.22 (1.50)	5.1 (1.4)	0.00528
FT (pg/mL)	5.62 (1.80)	6.83 (2.71)	0.0113

BMI, body mass index; BMD, bone mineral density; Hb, hemoglobin; TG, triglyceride; BS, blood sugar; PVR, post-voided residual volume; IPSS, International Index of Prostatic Symptom score; OABSS, Overactive Bladder Symptom score; TT, total testosterone; FT, free testosterone.

Table 3. Comparison of each parameter between baseline and 12-month visit in the two groups.

	Mean (SD)
	Baseline	12 months	p
Group A
BMI	23.3 (2.5)	23.3 (2.4)	0.318
BMD/YAM ratio (%)	105.4 (22.1)	106.5 (22.0)	0.0165
Muscle volume	3.7 (2.4)	3.6 (2.3)	0.199
Hb (mg/dL)	11.4 (1.2)	11.1 (1.1)	0.0721
TG (mg/mL)	146 (66)	144 (78)	0.457
LDL (mg/mL)	105 (26)	100 (25)	0.109
HDL (mg/mL)	54 (15)	52 (15)	0.0621
BS (mg/dL)	120 (28)	122 (32)	0.398
FT (ng/mL)	5.62 (1.80)	8.23 (3.48)	<0.001
Prostatic volume (mL)	46.6 (19.0)	29.4 (14.6)	<0.001
PVR (mL)	74 (78)	50 (60)	0.00458
IPSS	16.6 (7.6)	13.5 (7.9)	0.00109
OABSS	5.3 (3.9)	4.8 (3.2)	0.0366
IIEF5	5.9 (6.6)	5.6 (6.4)	0.107
Group B
BMI	23.4 (3.2)	23.4 (3.6)	0.391
BMD/YAM ratio (%)	101.5 (16.9)	102.3 (16.5)	0.203
Muscle volume	3.8 (2.0)	3.5 (2.1)	0.0967
Hb (mg/dL)	14.0 (3.3)	13.6 (3.6)	<0.001
TG (mg/mL)	131 (71)	128 (71)	0.24
LDL (mg/mL)	104 (26)	103 (28)	0.387
HDL (mg/mL)	52 (14)	49 (12)	0.0593
BS (mg/dL)	126 (39)	129 (42)	0.271
FT (ng/mL)	6.83 (2.71)	5.85 (2.14)	0.0173
Prostatic volume (mL)	45.9 (21.8)	33.7 (18)	<0.001
PVR (mL)	66 (68)	53 (65)	0.00948
IPSS	15.0 (7.5)	13.6 (7.9)	0.116
OABSS	5.1 (3.1)	4.3 (2.9)	0.0739
IIEF5	8.1 (7.6)	5.9 (7.7)	0.00514

BMI, body mass index; BMD, bone mineral density; Hb, hemoglobin; TG, triglyceride; BS, blood sugar; PVR, post-voided residual volume; IPSS, International Index of Prostatic Symptom score; OABSS, Overactive Bladder Symptom score; TT, total testosterone; FT, free testosterone.

Table 4. Comparison of changes from baseline to 12-month visit in the two groups.

	Mean (SD)
Variables	Group A (n = 42)	Group B (n = 34)	p
BMI	0.17 (0.74)	−0.26 (1.60)	0.0936
BMD/YAM ratio (%)	1.0 (2.8)	0.6 (3.5)	0.287
Muscle volume	−0.16 (1.27)	−0.29 (1.30)	0.333
Hb (mg/dL)	−0.13 (0.53)	−0.38 (0.76)	0.0859
TG (mg/mL)	−0.5 (60.3)	1.2 (46.9)	0.452
LDL (mg/mL)	−3.4 (17.8)	−1.6 (17.3)	0.329
HDL (mg/mL)	−2.0 (6.9)	−2.9 (6.4)	0.277
BS (mg/dL)	1.7 (26.5)	3.4 (32.0)	0.401
Rate of FT change (%)	54.2 (66.7)	−6.9 (37.0)	<0.001
Prostatic volume (mL)	−13.3 (11.1)	−12.4 (10.8)	0.375
PVR (mL)	−22.5 (81.2)	−15.5 (57.7)	0.341
IPSS	−3.1 (5.9)	−1.2 (7.3)	0.111
OABSS	−0.7 (2.2)	−0.9 (2.8)	0.355
IIEF5	−0.4 (1.0)	−2.3 (4.7)	0.0830

BMI, body mass index; BMD, bone mineral density; Hb, hemoglobin; TG, triglyceride; BS, blood sugar; PVR, post-voided residual volume; IPSS, International Index of Prostatic Symptom score; OABSS, Overactive Bladder Symptom score; TT, total testosterone; FT, free testosterone.